- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07554573
Evaluación de la clasificación de biofirmas de CDIS para el beneficio de la radioterapia después de la tumorectomía (ABCD RT) (ABCD RT)
Ensayo aleatorizado de fase III: Evaluación de la clasificación de biofirmas del DCIS para beneficio de radioterapia post tumorectomía (ABCD RT)
NRG-CC016 is being done to determine if omission of radiation therapy (RT) for patients with biosignature Low Risk (DCISionRT score less than 2.8) DCIS yields no clinically meaningful increase ipsilateral breast recurrence (IBR) compared to those treated with RT (Cohort A).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Current DCIS treatment decisions rely on clinical-pathologic criteria that have remained unchanged for over 50 years. Even in favorable patients, RT provides an absolute benefit (~8%), which is considered clinically meaningful.
However, DCISionRT retrospective data suggests that approximately 37% of patients (Low Risk) may safely omit RT with less than 1% absolute difference in IBR. This could impact around 22,470 women annually in the US. Further, approximately one-third of Grade 3 DCIS patients (who have biosignature Low Risk scores) may also safely omit RT.
From a number-needed-to-treat (NNT) perspective, RTOG 9804 results suggest that to prevent an IBR the NNT ≈ 13. In contrast, the DCISionRT data for biosignature Low Risk, the NNT ≈ 125. This represents a major shift in treatment value.
In addition, shorter RT regimens have increased RT utilization, raising concerns about overtreatment. Biosignature-guided care could better balance overtreatment versus undertreatment.
For high-risk DCIS, there have been no NCTN trials in over 20 years (last being ECOG 5194). NRG CC016 would be the first trial since then to include high-risk DCIS by both clinical-pathology and biosignature (score greater than 2.8 - Cohort B) criteria and determine the clinical utility of biosignature risk categorization over patient age and tumor grade, size and hormone receptor status. It will also prospectively assess outcomes for the subsets of Elevated Risk (~40% of DCIS) and Residual Risk (~20% of DCIS) patients treated with standard-of-care breast RT, with anticipated 10-year IBR rates of 5% and 15%, respectively.
The study addresses multiple critical gaps:
- First prospective assessment of a biosignature to determine its clinical utility in risk assessment for DCIS.
- Determine if biosignature Low Risk patients gain no clinically meaningful benefit from RT.
- Prospective assessment of outcomes in Elevated and Residual Risk groups.
- Evaluation of boost benefit in higher-risk subgroups.
- Evaluation of patient-reported outcomes including worry and quality of life (Section 11.1) for DCIS.
This trial will randomize Low Risk biosignature patients to test the non-inferiority of RT-omission and prospectively determine outcomes in Elevated Risk and Residual Risk biosignature groups treated with RT. If published retrospective data are reproduced prospectively here, this would:
- Redefine standard-of-care treatment for DCIS through use of a biosignature.
- Enable safe omission of RT in selected patients (Low Risk) regardless of clinical-pathologic criteria with excellent outcomes.
- Identify a subset of DCIS (Elevated Risk) with similar excellent outcomes following breast RT.
- Identify a specific subset of DCIS (Residual Risk) in need of additional intervention.
- Represent the first prospective assessment of a radiation-specific biosignature in oncology.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Director Regulator y Affairs
- Número de teléfono: 412-339-5300
- Correo electrónico: langerj@nrgoncology.org
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- The patient or a legally authorized representative must provide study-specific informed consent prior to Step 1/Registration and, for patients treated in the U.S., authorization permitting release of personal health information.
Breast and Disease Assessment
- The patient must be female and greater than or equal to 30 and less than or equal to 85 years of age. (Note: The DCISionRT test is validated only in women between the ages of 30 and 85.)
- The patient must have a diagnosis of DCIS less than or equal to 6 cm. (Note: The DCISionRT test is validated only in women with DCIS less than or equal to 6 cm.)
- The patient must have an ECOG performance status of less than or equal to 2 (or Karnofsky greater than or equal to 50%).
- The patient must have had a bilateral mammogram within 6 months prior to registration.
- The patient must have undergone breast conserving surgery with negative surgical margins (greater than or equal to 2 mm). Margin status is assessed on lumpectomy specimen and/or additional margins as determined by the local pathologist. If pathologic examination demonstrates DCIS less than 2 mm from resection edge, additional excisions may be performed to obtain clear margins. Patients with lobular carcinoma in situ (LCIS), atypical lobular hyperplasia (ALH), and/or atypical ductal hyperplasia (ADH) are eligible regardless of margins for these histologies.
- The patient must have no suspicious unresected microcalcification, densities, or palpable abnormalities (in the ipsilateral or contralateral breast) unless biopsied and found to be benign.
- The interval between the last surgery for DCIS (including re-excision of margins) and registration must be no more than 70 days
- The following staging criteria must be met postoperatively according to AJCC 8th edition criteria:
- Primary tumor must be pTis
- Patients must be cN0 (by physical exam and/or imaging)
- Axillary surgery staging with sentinel node biopsy and/or axillary node dissection is not required. If surgical axillary staging was performed, ipsilateral nodes must be pN0. (Patients with pathologic staging of pN0 (i+) or pN0)(mol+) are NOT eligible.
- DCIS may be of any grade (1-3).
- The DCIS must be tested for estrogen receptor (ER) and progesterone receptor (PgR) status, either on an initial core biopsy or surgical specimen, by current ASCO/CAP Guideline Recommendations for hormone receptor testing. Any ER and/or PgR receptor status is eligible.
- Participants must have unilateral DCIS diagnosed within 4 months of registration without a history of prior ipsilateral or contralateral DCIS or invasive breast cancer.
- DCISionRT result must have been either previously obtained or the patient has consented to submission of specimen for centralized testing by PreludeDx.
- The patient must have recovered from surgery with the incision well healed and no signs of infection.
- The patient must have no contraindications to standard-of-care breast radiotherapy (i.e., active collagen-vascular disease, scleroderma, prior breast/chest radiotherapy).
Co-morbid and Other Conditions
- Patients of childbearing potential must have a negative pregnancy test within 14 days of registration, have no intention of becoming pregnant for 120 days following registration and be willing to use highly effective contraception if randomized to RT from registration until 1 month after completion of RT.
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the treatment regimen are eligible for this trial.
- If germ-line testing performed, results must be reviewed and indicate no pathogenic or likely pathogenic variants associated with increased breast cancer risk. (Variants of unknown significance are acceptable.)
Medications
- Patients must discontinue postmenopausal hormone replacement therapy, including estrogens or progesterone formulations prior to study entry. Low-dose vaginal estrogen creams, tablets, rings, or IUDs are allowed. For patients treated with anti-endocrine therapy as chemoprevention for the development of breast cancer, anti-endocrine therapy must have been discontinued greater than 6 months prior to the diagnosis of DCIS.
- Adjuvant anti-endocrine therapy is a standard treatment option for ER or PgR positive DCIS. Patients may not have a history of taking oral anti-endocrine therapy (SERMS, SERDS, or aromatase inhibitors) prior to DCIS diagnosis. Adjuvant anti-endocrine therapy for DCIS may not be initiated prior to DCISion RT testing.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Cohort A Arm 1, Breast Radiation Therapy
Radiation therapy to breast for patients with DCISionRT score less than or equal to 2.8. |
Post-lumpectomy RT will be external beam radiation to the whole breast ± boost (sequential or integrated) or Partial Breast Irradiation (PBI). RT must begin within 112 days of the last breast cancer surgery (lumpectomy or re-excision of margins). |
|
Comparador activo: Cohort A Arm 2, No Breast Radiation Therapy
No radiation therapy to breast for patients with DCISionRT score less than or equal to 2.8. |
No intervention. |
|
Otro: Cohort B
Patients with DCISionRT score greater than 2.8. |
Patients will continue treatment with standard of care breast radiation therapy at the investigator's discretion. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to Ipsilateral Breast Recurrence (IBR) in Cohort A patients
Periodo de tiempo: 10 years
|
Cumulative incidence of IBR. |
10 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to IBR in Cohort B patients
Periodo de tiempo: 10 years
|
Cumulative incidence of IBR evaluated separately for Elevated Risk patients (defined as DCISionRT score > 2.8, excluding score of 9.2) and Residual Risk patients (defined as DCISionRT score = 9.2). |
10 years
|
|
Time to IBR in the subset of Cohort A and Cohort B patients with discordant clinical-pathology and biosignature risk categories
Periodo de tiempo: 10 years
|
Cumulative incidence of IBR evaluated separately for the subsets of Cohort A patients with high-risk clinical-pathologic features (age < 50 or Grade 3 disease or ER- PR-negative or tumors > 2.5 cm in size) and for Cohort B subsets of Elevated Risk and Residual Risk patients , with low-risk clinical-pathologic features (Grade 1-2, tumor ≤ 2.5 cm, ER- and/or PR-positive, age ≥ 50) |
10 years
|
|
Time to invasive IBR
Periodo de tiempo: 10 years
|
Cumulative incidence of invasive IBR in Cohort A and Cohort B patients |
10 years
|
|
Time to IBR-DCIS
Periodo de tiempo: 10 years
|
Cumulative incidence of IBR-DCIS in Cohort A and Cohort B patients |
10 years
|
|
Breast cancer-free interval (BCFI)
Periodo de tiempo: 10 years
|
Cumulative incidence of BCFI events in Cohort A and Cohort B patients |
10 years
|
|
Time to contralateral breast cancer
Periodo de tiempo: 10 years
|
Cumulative incidence of contralateral breast cancer events in Cohort A and Cohort B patients |
10 years
|
|
Overall survival
Periodo de tiempo: 10 years
|
Percentage of patients alive in Cohort A and Cohort B patients |
10 years
|
|
Ipsilateral mastectomy events
Periodo de tiempo: 15 years
|
Cumulative incidence of Ipsilateral mastectomy events in Cohort A and Cohort B patients |
15 years
|
|
Patient-reported worry about recurrence
Periodo de tiempo: 1 year
|
Patient-reported worry about recurrence as measured by Cancer Worry Scale in Cohort A and Cohort B (evaluated separately for Elevated and Residual Risk) patients |
1 year
|
|
Time to subsequent breast events (SBE)
Periodo de tiempo: 10 years
|
Cumulative incidence of SBE events in Cohort B patients who initiate anti-endocrine therapy |
10 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Carcinoma de mama in situ
- Neoplasias por sitio
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Enfermedades de la piel
- Enfermedades de los senos
- Carcinoma
- Neoplasias ductales, lobulillares y medulares
- Carcinoma in situ
- Enfermedades de la piel y del tejido conectivo
- Neoplasias de mama
- Carcinoma Intraductal No Infiltrante
- Terapéutica
- Radioterapia
Otros números de identificación del estudio
- NRG-CC016
- 5U10CA180868 (Subvención/contrato del NIH de EE. UU.)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .